Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Neurophysiol ; 124(10): 1975-85, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23684127

ABSTRACT

OBJECTIVE: The problem of identifying, in advance, the most effective treatment agent for various psychiatric conditions remains an elusive goal. To address this challenge, we investigate the performance of the proposed machine learning (ML) methodology (based on the pre-treatment electroencephalogram (EEG)) for prediction of response to treatment with a selective serotonin reuptake inhibitor (SSRI) medication in subjects suffering from major depressive disorder (MDD). METHODS: A relatively small number of most discriminating features are selected from a large group of candidate features extracted from the subject's pre-treatment EEG, using a machine learning procedure for feature selection. The selected features are fed into a classifier, which was realized as a mixture of factor analysis (MFA) model, whose output is the predicted response in the form of a likelihood value. This likelihood indicates the extent to which the subject belongs to the responder vs. non-responder classes. The overall method was evaluated using a "leave-n-out" randomized permutation cross-validation procedure. RESULTS: A list of discriminating EEG biomarkers (features) was found. The specificity of the proposed method is 80.9% while sensitivity is 94.9%, for an overall prediction accuracy of 87.9%. There is a 98.76% confidence that the estimated prediction rate is within the interval [75%, 100%]. CONCLUSIONS: These results indicate that the proposed ML method holds considerable promise in predicting the efficacy of SSRI antidepressant therapy for MDD, based on a simple and cost-effective pre-treatment EEG. SIGNIFICANCE: The proposed approach offers the potential to improve the treatment of major depression and to reduce health care costs.


Subject(s)
Artificial Intelligence , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/drug therapy , Electroencephalography/methods , Selective Serotonin Reuptake Inhibitors/therapeutic use , Adult , Confidence Intervals , Female , Humans , Male , Middle Aged , Sensitivity and Specificity , Treatment Outcome , Young Adult
2.
Clin Neurophysiol ; 121(12): 1998-2006, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21035741

ABSTRACT

OBJECTIVE: To investigate whether applying advanced machine learning (ML) methodologies to pre-treatment electroencephalography (EEG) data can predict the response to clozapine therapy in adult subjects suffering from chronic schizophrenia. METHODS: Pre-treatment EEG data are collected in 23+14 schizophrenic adults. Treatment outcome, after at least one year follow-up, is determined using clinical ratings by a trained clinician blind to EEG results. First, a feature selection scheme is employed to select a reduced subset of features extracted from the subjects' EEG that is most statistically relevant to our treatment-response prediction. These features are then entered into a classifier, which is realized in the form of a kernel partial least squares regression method that performs response prediction. Various scales, including the positive and negative syndrome scale (PANSS) are used as treatment-response indicators. RESULTS: We determined that a set of discriminating EEG features do exist. A low-dimensional representation of the feature space showed significant clustering into clozapine responder and non-responder groups. The minimum level of performance of the proposed prediction methodology, tested over a range of conditions using the leave-one-out cross-validation method using the original 23 subjects, with further testing in an independent sample of 14 subjects, was 85%. CONCLUSIONS: These findings indicate that analysis of pre-treatment EEG data can predict the clinical response to clozapine in treatment resistant schizophrenia. SIGNIFICANCE: If replicated in a larger population, this novel approach to EEG analysis may assist the clinician in determining treatment-efficacy.


Subject(s)
Antipsychotic Agents/therapeutic use , Artificial Intelligence , Clozapine/therapeutic use , Electroencephalography/methods , Schizophrenia/drug therapy , Adult , Discrimination, Psychological , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pilot Projects , Predictive Value of Tests , Psychiatric Status Rating Scales , Reproducibility of Results , Schizophrenia/physiopathology , Sensitivity and Specificity , Treatment Outcome
3.
Schizophr Res ; 119(1-3): 228-31, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20100649

ABSTRACT

Heat shock proteins act as intracellular chaperones by assisting with proper protein folding in response to various cellular stresses. In doing so, these proteins protect the cell from unwanted protein aggregation, which in turn, plays an important role in the pathogenesis of numerous disorders. Previous reports from our laboratory have described a 40 kDa catecholamine regulated heat shock-like protein (CRP40), an alternate gene product of the 70 kDa mitochondrial heat shock protein, mortalin. CRP40 shares an intimate association with dopaminergic activity, specifically as it pertains to dopamine dysregulation in schizophrenia. This study investigates human CRP40/mortalin mRNA expression within dorsolateral prefrontal cortex postmortem specimens from normal control, schizophrenic and bipolar patients obtained from the Stanley Medical Research Institute. Real-time polymerase chain reaction was carried out for all patient samples (n=105; n=35 per group) in a blinded manner. No significant alterations in CRP40/mortalin mRNA expression levels were observed between control, bipolar and schizophrenic patients. However, multiple regression demonstrated a distinct positive correlation between CRP40/mortalin mRNA expression and lifetime use of antipsychotic drugs within the schizophrenic patient profile, after controlling for important confounding factors. Thus, the data suggest that human CRP40/mortalin is modulated by dopaminergic activity and may act to protect neurons from excess catecholamine activity in regions of the brain associated with psychosis.


Subject(s)
Antipsychotic Agents/therapeutic use , Bipolar Disorder/drug therapy , Bipolar Disorder/genetics , HSP70 Heat-Shock Proteins/genetics , Nerve Tissue Proteins/genetics , Prefrontal Cortex/pathology , RNA, Messenger/genetics , Schizophrenia/drug therapy , Schizophrenia/genetics , Adult , Bipolar Disorder/pathology , Dopamine/metabolism , Female , Gene Expression/genetics , Humans , Hydrogen-Ion Concentration , Male , Middle Aged , Neurons/pathology , Reference Values , Regression Analysis , Schizophrenia/pathology , Statistics as Topic
4.
Can J Psychiatry ; 51(9): 575-80, 2006 Aug.
Article in English | MEDLINE | ID: mdl-17007224

ABSTRACT

OBJECTIVE: To undertake a preliminary study to assess the feasibility of clinical implementation and evaluate the effectiveness of a novel adventure- and recreation-based group intervention in the rehabilitation of individuals with schizophrenia. METHODS: In a 2-year, prospective, case-control study, 23 consecutively referred, clinically stabilized schizophrenia patients received the new intervention over an 8-month period; 31 patients on the wait list, considered the control group, received standard clinical care that included some recreational activities. Symptom severity, self-esteem, self-appraised cognitive abilities, and functioning were documented for both groups with standardized rating scales administered at baseline, on completion of treatment, and at 12 months posttreatment. RESULTS: Treatment adherence was 97%, and there were no dropouts. Patients in the study group showed marginal improvement in perceived cognitive abilities and on domain-specific functioning measures but experienced a significant improvement in their self-esteem and global functioning (P < 0.05), as well as a weight loss of over 12 lb. Improvement was sustained over 1 year with further occupational and social gains. CONCLUSION: In the context of overcoming barriers to providing early intervention for youth and preventing metabolic problems among older adults with schizophrenia, adventure- and recreation-based interventions could play a useful complementary role.


Subject(s)
Psychotherapy/methods , Quality of Life , Recreation , Schizophrenia/rehabilitation , Social Support , Weight Loss , Adult , Case-Control Studies , Deinstitutionalization , Feasibility Studies , Female , Humans , Male , Patient Compliance/statistics & numerical data , Prospective Studies , Self Efficacy , Treatment Outcome
5.
Clin Neurophysiol ; 114(5): 883-8, 2003 May.
Article in English | MEDLINE | ID: mdl-12738434

ABSTRACT

OBJECTIVE: To quantify the extent of disagreement among expert artefactors, to compare their results with a 'minimalist' approach where only gross artefacts were removed, and to relate the result to frequency and to cranial location. METHODS: Raw QEEG records for 12 subjects were artefacted by 6-expert, and one 'minimalist', artefactor. Standard errors (SEs) of measurement were computed for each of 20 1.2 Hz frequency bins in each of 20 electrode positions. RESULTS: SEs declined with frequency. SEs associated with the 'minimalist' were comparable to those of the experts. The high SEs in delta were confined to the frontal and frontotemporal regions. SEs were small and uniform over the cranium for frequencies greater than 5.2 Hz. CONCLUSIONS: Artefactor unreliability is a serious problem in the delta band because of disagreement on eye movement artefacts. The success of the 'minimalist' suggests that automated methodologies may be a feasible alternative to the use of expert technicians. SIGNIFICANCE: A novel statistical procedure proves helpful in elucidating the sources of artefactor error and points to possible remedies.


Subject(s)
Artifacts , Brain Mapping/methods , Electroencephalography/methods , Adult , Cerebral Cortex/physiology , Confidence Intervals , Female , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...